Factor XIII levels, clot strength, and impact of fibrinogen concentrate in infants undergoing cardiopulmonary bypass: a mechanistic sub-study of the FIBCON trial. (February 2023)

• Record Type: Journal Article
• Authors: Siemens, Kristina; Hunt, Beverley J.; Parmar, Kiran; Taylor, Dan; Salih, Caner; Tibby, Shane M.
• Is Part Of: British journal of anaesthesia. Volume 130:Number 2(2023)
• Page Start: 175
• Page End: 182
• Publication Date: 2023-02
• Subjects: cardiac surgery -- cardiopulmonary bypass -- factor XIII -- fibrinogen -- haemostasis -- thromboelastometry; Anesthesiology -- Periodicals; Anesthesia -- Periodicals; 617.9605
• DOI: 10.1016/j.bja.2022.09.022
• Languages: English
• ISSNs: 0007-0912

Abstract

Abstract: Background: Acquired factor XIII (FXIII) deficiency after major surgery can increase postoperative bleeding. We evaluated FXIII contribution to clot strength and the effect of fibrinogen concentrate administration on FXIII activity in infants undergoing cardiac surgery using cardiopulmonary bypass. Methods: We conducted a prospectively planned, mechanistic sub-study, nested within the Fibrinogen Concentrate Supplementation in the Management of Bleeding During Paediatric Cardiopulmonary Bypass: A Phase 1B/2A, Open-Label Dose Escalation Study (FIBCON) trial, which investigated fibrinogen concentrate supplementation during cardiopulmonary bypass (ISRCTN: 50553029) in 111 infants (median age 6.4 months). The relationships between platelet number, fibrinogen concentration, and FXIII activity with rotational thromboelastometry clot strength (EXTEM-MCF) in blood taken immediately before cardiopulmonary bypass and after separation from bypass were estimated using multivariable linear regression. Changes in coagulation variables over time were quantified using a generalised linear model comparing three groups: fibrinogen concentrate-supplemented infants, placebo, and a third cohort with lower bleeding risk. Results: Overall, 48% of the variability (multivariable R 2 ) in EXTEM-MCF clot strength was explained by three factors: the largest contribution was from FXIII activity (partial R 2 =0.21), followed by platelet number (partial R 2 =0.14), and fibrinogen concentration (partial R 2 =0.095). During cardiopulmonary bypass, mean platelet count fell by a similar amount in the three groups (–36% to –41%; interaction P =0.98). Conversely, fibrinogen concentration increased in all three groups: 132% in the fibrinogen concentrate-supplemented group, 26% in the placebo group, and 51% in the low-risk group. A similar increase was observed for FXIII activity (61%, 23%, and 25%, respectively; interaction P <0.0001). Conclusions: FXIII contribution to clot strength is considerable in infants undergoing cardiac surgery. Fibrinogen concentrate supplementation also increased FXIII activity, and hence clot strength. Clinical trial registration: ISRCTN: 50553029.